沙美特罗替卡松干粉吸入剂治疗咳嗽变异性哮喘的疗效观察被引量：1

Curative effect observation of Salmeterol and Fluticasone Propionate dry powder inhaler Treatment of cough variant asthma

下载PDF

导出

摘要目的观察沙美特罗替卡松干粉(舒利迭)吸入剂治疗咳嗽变异性哮喘(cough variant asthma,CVA)患者的临床疗效。方法 32例CVA给予舒利迭(沙美特罗/替卡松50μg/250μg)吸入治疗8周后的咳嗽变化情况及肺功能改善情况。结果患者咳嗽严重程度持续下降,症状改善迅速,昼夜呼气峰值流速变异率≤20%,差异有统计学意义(P<0.05)。结论舒利迭吸入剂可快速有效改善CVA患者症状,应用方便安全。 Objective To observe the powder salmeterol and fluticasone propionate （Seretide） inhaler treatment of cough variant asthma （cough variant asthma,CVA） in patients with clinical efficacy. Methods 32 patients with CVA were treaded with Seretide （salmeterol/fluticasone 50μg /250μg） after 8 weeks treatment of inhalation cough and pulmonary function changes to improve the situation. The results continued to decline in patients with cough severity,the symptoms improved rapidly,day and night peak expiratory flow rate variation ≤ 20% ,the difference was statistically significant （P 0.05） . Conclusion Seretide inhaler can be quickly and effectively improve symptoms in patients with CVA,convenient and safe applications.

作者张秀丽

机构地区河南省商丘市第一人民医院RICU

出处《中国实用医药》 2013年第20期28-29,共2页 China Practical Medicine

关键词沙美特罗替卡松干粉吸入剂咳嗽变异性哮喘 Salmeterol and fluticasone propionate dry powder inhaler Cough variant asthma

分类号 R562.25 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献9

1殷凯生.以临床控制作为防治哮喘的目标[J].实用临床医药杂志,2008,12(3):1-2. 被引量：8
2Bateman ED, Boushey HA, BousquetJ, et al. can guideline-defined asthma control, beachieved? The Gaining optimal Asthma Control Study. AmJ Respir Crit Care Med,2004,170:836-844.
3O' Byme PM. Global Strategy for asthma management and prevention [ DB/CL ]. Hamilton; GINA Executive committee,2006 [ 2007-7- 11 ], http ://www. Ginaasthma. com.
4中华医学会呼吸病学分会哮喘学组.咳嗽的诊断与治疗指南(草案)[J].中华结核和呼吸杂志,2005,28(11):738-744. 被引量：1456
5中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗及教育和管理方案)[J].中华结核和呼吸杂志,2003,26(3):132-138. 被引量：3565
6张颖,王伟.咳嗽变异型哮喘的研究进展[J].国外医学（呼吸系统分册）,2004,24(3):160-161. 被引量：50
7Matsumoto H, Niimi A, Tabuena RP, et al. Airway wall thickening inpatients with cough variant asthma and non-asthmatic chronic cough. Chest,2007,131 : 1042,1049.
8Fujimura M, Nishizawa Y, Nishitsuji M, et al. Predictors for typical asthma onset from cough variant asthma. J Asthma, 2005, 42: 107-111.
9Nakajima T, Nishiuma Y, Nishiuma T, et al. Characteristics of patients with chronic cough who developed classic asthma during the course of cough variant asthma: a longitudinal study. Respiration, 2005,72:606-611.

二级参考文献18

1McFadden ER.Exertional dyspnea and cough as preludes to acute attacks of bronchial asthma.Nengl J Med,1975,292:555.
2Johnson D,OsbornLM.Cough variant asthma: a review of clinical literature.J Asthma,1991,28:85-90.
3Niimi A,Amitani R,Suzuki K,et al.Eosinophilic inflammation in cough variant asthma.Eur Respir J,1998,11:1064-1069.
4Orejas GC,Pascual PT,Alzueta AA,et al.Cough variant asthma.Clinical and functional characteristics.Report of 63 cases.Arch Bronconeumol,1998,34:232-236.
5Fujimura M,Ogawa H,Nishizawa Y,et al.Comparison of atopic cough with cough variant asthma: is atopic cough a precursor of asthma? Thorax,2003,58:14-18.
6Doan T,Patterson R,Greenberger PA.Cough variant asthma: Usefulness of a diagnostic-therapeutic trial with prednisone.Ann Allergy,1992,69:505-509.
7Cheriyan S,Greenberger PA,Patterson R.Outcome of cough variant asthma treated with inhaled steroids.Ann Allergy,1994,73:478-480.
8Dicpinigaitis PV,Dobkin JB,Reichel J.Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma.J Asthma,2002,39:291-297.
9Shioya T,Satake M,Sano M,et al.Effect of suplatast tosilate,a Th2 cytokine inhibitor,on cough variant asthma.Eur J Clin Pharmacol,2002,58:171-176.
10McGarvey LPA,Heaney LG,Lawson JT,et al.Evaluation and outcome of patients with chronic non-productive cough using a comprehensive diagnostic protocol.Thorax,1998,53:738-743.